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Abstract Magnolol, a compound extracted from the
Chinese medicinal herb Magnolia oYcinalis, has sev-
eral biological eVects. However, its protective eVects
against endothelial injury remain unclear. In this study,
we examined whether magnolol prevents oxidized low
density lipoprotein (oxLDL)-induced vascular endo-
thelial apoptosis. Incubation of oxLDL with magnolol
(2.5–20 M) inhibited copper-induced oxidative modi-
Wcation via diene formation, thiobarbituric acid reac-
tive substances (TBARS) assay and electrophoretic
mobility assay. Apoptotic cell death as characterized
by terminal deoxynucleotidyl transferase-mediated
dUTP nick end-labeling (TUNEL) stain. We measured
the production of reactive oxygen species (ROS) by
using the Xuorescent probe 2,7-dichloroXuorescein
acetoxymethyl ester (DCF-AM), and observed the
activity of antioxidant enzymes. Furthermore, several
apoptotic signaling pathways which showed NF-B
activation, increased cytosolic calcium, alteration of
mitochondrial membrane potential, cytochrome c
release and activation of caspase 3 were also investi-
gated. We demonstrated that magnolol prevented the
copper-induced oxidative modiWcation of LDL. Mag-
nolol attenuated the oxLDL-induced ROS generation
and subsequent NF-B activation. Furthermore, intra-
cellular calcium accumulation and subsequent mito-
chondrial membrane potential collapse, cytochome c
release and activation of caspase 3 caused by oxLDL
were also inhibited by magnolol. Our results suggest
that magnolol may have clinical implications in the pre-
vention of atherosclerotic vascular disease through
decreasing the oxLDL-induced ROS production.
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Introduction
A high plasma level of cholesterol is a well-known risk
factor for atherosclerotic disease. Oxidation of low
density lipoprotein is believed to play an important
role in the pathogenesis of atherosclerosis. In early ath-
erosclerotic lesions, the amount of oxidized LDL
(oxLDL) is usually low and exerts a mainly proinXam-
matory eVect (Cushing et al. 1990). In more advanced
atherosclerotic lesions, increased accumulation of
oxLDL containing more peroxidation products may
generate a cytotoxic eVect contributing to plaque degen-
eration and rupture. OxLDL alters the intracellular
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422 Arch Toxicol (2007) 81:421–432redox status of the cells, in part through the generation
of reactive oxygen species (ROS), and has been
implicated as an important pro-oxidant signal in endo-
thelial cells (Berliner et al. 1995). ROS regulation of
signal transduction components include modiWcations
of the activity of transcriptional factors such as NF-B,
a vital signaling factor for several vascular events,
resulting in changes in gene expression and modiWca-
tions in cellular responses, which may contribute to
oxLDL-induced apoptosis (Harada-Shiba et al. 1998;
Heermeier et al. 1999). Hsieh et al. (2001) demon-
strated that ROS generation and apoptosis were tightly
coupled in oxLDL-treated vascular cells. In addition,
antioxidants that reduced ROS level inhibited apopto-
sis, while those that did not reduce ROS level were
ineVective.
Magnolol, an active component isolated from the
herb ‘Houpo’ (Magnolia oYcinalis), is widely used in
the treatment of a number of diseases in traditional
Chinese medicine due to its anti-allergic eVects (Tohda
et al. 1999), anxiolytic eVects, anti-ulcer eVects (Ikar-
ashi et al. 2001) and inhibitory eVects on skin tumors
(Ikeda and Nagase 2002). It has been shown to possess
antioxidant activity approximately 1,000 times greater
than -tocopherol (Lo et al. 1994). Therefore, it is
expected that magnolol might play an important role in
preventing the proatherogenic stimuli which leads to
increased production of ROS within endothelial cells.
Early studies have shown that magnolol protected rat
heart mitochondria against lipid peroxidation (Lo et al.
1994), and free radical mediated cerebral ischaemic
injury (Chang et al. 2003), reduced superoxide anion
production and myeloperoxidase activity, an index of
neutrophil inWltration in the ischemic myocardium
(Lee et al. 2001). However, the molecular and cellular
mechanisms of magnolol on oxLDL-induced endothe-
lial apoptosis were not fully elucidated. To test the
hypothesis that magnolol may have eVects on the pre-
vention of atherosclerosis, we undertook the current
study to explore whether magnolol prevented oxida-
tive modiWcation of LDL and protected against
oxLDL-induced cytotoxicity. Apoptotic signaling
including ROS generation, NF-B activation, intracel-
lular calcium accumulation, mitochondrial destabiliza-
tion and activation of caspase 3 were also investigated.
Materials and methods
Chemicals
Magnolol was prepared as previously described (Yang
et al. 2003). Chemicals were obtained from the following
companies: M199, fetal bovine serum, and trypsin-
EDTA from Gibco (Grand Island, NY, USA); low
serum growth supplement (Cascade, OR, USA), 4,6-
diamidino-2-phenylindole (DAPI), ethylene diamino-
tetraacetic acid (EDTA), penicillin, and streptomycin
from Sigma (St. Louis, MO, USA); lactate dehydroge-
nase (LDH) kits and TUNEL staining kit from Boeh-
ringer Mannheim (Mannheim, Germany); superoxide
dismutase activity assay kit from Calbiochem (San
Diego, CA, USA); Fura 2-AM, DCF-AM from
Molecular Probes (Eugene, OR, USA); 5,58,6,68-
tetraethylbenzimidazolcarbocyanine iodide (JC-1)
and anti-active caspase 3 from BioVision (Palo Alto,
CA, USA).
Cell cultures
Human umbilical vein endothelial cells (HUVECs) were
isolated from human umbilical cord with collagenase and
used at passage 2–3 (JaVe et al. 1973). After dissociation,
the cells were collected and cultured on gelatin-coated
culture dishes in medium 199 with low serum growth sup-
plement, 100 IU/ml penicillin, and 0.1 mg/ml streptomy-
cin. Subcultures were performed with trypsin-EDTA.
Media were refreshed on every second day. The identity
of umbilical vein endothelial cells was conWrmed by their
cobblestone morphology and strong positive immunore-
activity to von Willebrand factor.
Lipoprotein separation
Native LDL was isolated and oxidatively modiWed from
fresh normolipidemic human serum by sequential ultra-
centrifugation as previously described (Havel et al.
1955). Immediately before oxidation tests LDL was
separated from EDTA and from diVusible low molecu-
lar mass compounds by gel Wltration on PD-10 Sepha-
dex G-25 M gel (Pharmacia) in 0.01 mol/l phosphate-
buVered saline (136.9 mmol/l NaCl, 2.68 mmol/l KCl,
4 mmol/l Na2HPO4, 1.76 mmol/l KH2PO4) pH 7.4.
EDTA-free LDL was immediately used for the mea-
surement of the kinetics of LDL oxidation by continu-
ously monitoring the change in the absorbency of
conjugated dienes at 232 nm at 37°C. Absorbance was
measured with a Beckman DU740 spectrophotometer
equipped with a six-position automated cuvette changer
and a Peltier temperature controller (Beckman Instru-
ments, Mississauga, ON, Canada), essentially as
described by Esterbauer et al (1989). BrieXy, 100 g of
LDL (protein) was diluted with 0.01 M phosphate-
buVered saline, and oxidation was initiated by 10 M
CuSO4 (Wnal concentration). Absorbance was recorded
every 10 min, and the kinetics of oxidation were123
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jugated dienes at 37°C for up to 7 h. The lag time (lag
phase, resistance time) was deWned as the point at
which the initial slope representing the initiation rate
and the point at which the propagation slope inter-
sected. This was calculated from the kinetic plot of the
change of absorbance versus time as described previ-
ously (Wilson et al. 2002). In some experiments, LDL
oxidation was also measured by thiobarbituric acid
reactive substances (TBARS) as described previously
(Buege and Aust 1978). Malondialdehyde was used as a
standard. LDL oxidation was also checked by measur-
ing the electrophoretic mobility of LDL on a 1% aga-
rose gel in 0.1 M Tris–HCl pH 8.6. The gel was stained
with Sudan Black as previously described (Terpstra
et al. 1981). Depending on the degree of oxidation, the
electrophoretic mobility of freshly oxidized LDL was
approximately 1.4–1.7 times that of native LDL. The
Cu++-modiWed LDL (1 mg protein/ml) was prepared by
exposing LDL to 10 M CuSO4 for 16 h at 37°C. Pro-
tein levels were measured by the methods of Bradford
(Bradford 1976).
Determination of cytotoxicity and indices of apoptosis
To determine the eVects of magnolol on the oxLDL-
induced cytotoxicity, HUVECs were Wrst incubated
with magnolol (0.1–20 M) for 2 h and then stimulated
with oxidized LDL (200 g/ml) for 16 h. At the end of
stimulation, mitochondrial dehydrogenase activity was
used as an index of cell viability and was assessed using
MTT assay (Denizot and Lang 1986), and the lactate
dehydrogenase (LDH) released was analyzed for the
loss of plasma membrane integrity by using an LDH
diagnostic kit according to the manufacturer’s instruc-
tions. Apoptotic cells were determined by a terminal
deoxynucleotidyl transferase-mediated dUTP nick
end-labeling (TUNEL) assay under Xuorescence
microscopy or Xow cytometer.
Measurement of ROS production
ROS, such as superoxide (O2
¡ ) and hydrogen peroxide
(H2O2), are speciWc mediators of atherogenic stimuli
that induce leukocyte adhesion to endothelial cells.
The role of ROS in oxLDL-mediated cytotoxicity has
been reported recently, in particular through the acti-
vation of the caspase cascade and apoptosis (Hsieh
et al. 2001). The eVect of magnolol on ROS production
in HUVECs was determined by a Xuorometric assay
using 2,7-dichloroXuorescein acetoxymethyl ester
(DCF-AM, Molecular Probes) as a probe for the pres-
ence of hydroxyl radicals. After preincubation for 2 h
with the indicated concentrations of magnolol (2.5–
20 M), HUVECs were incubated with DCF-AM for
1 h and followed by incubation with 200 g/ml oxLDL
for indicated time periods. The Xuorescence intensity
was measured at 485-nm excitation and 538-nm emis-
sion using a Xuorescence microplate reader (Labsys-
tem, CA, USA).
Measurement of superoxide dismutase (SOD)
To determine the eVects of magnolol on antioxidant
enzymes after oxLDL treatment, SOD activity in the
homogenate was determined by an enzymatic assay
method using a commercial kit (Calbiochem) accord-
ing to the manufacturer’s instructions. Enzyme activity
was converted to U/mg protein.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay was performed
according to the method described by Aikawa et al.
(2002) with minor modiWcations. HUVECs were pre-
treated for 2 h with or without indicated concentra-
tions of magnolol followed by oxLDL (200 g/ml)
incubation for 1 h. Afterwards, HUVECs were gently
harvested and washed twice with ice-cold PBS contain-
ing 0.3 mM PMSF, the nuclear fraction was extracted
from the cell pellet of the cells using a NE-PER nuclear
and cytoplasmic reagent. A double stranded oligonu-
cleotide 5-AGTTGAGGGGACTTTCCCAGGC-3
used in our EMSA experiment contains the consensus
NF-B element in the  light-chain enhancer, 5-GGG
ACTTTCC-3 (5-GGGRNYYYCC-3; R is an unspeci-
Wed purine; Y is an unspeciWed pyrimidine; and N is
any nucleotide) (Chen et al. 1998). Ten microgram of
the nuclear fraction was incubated at 30°C for 30 min
in the presence of 1 g poly (dI-dC) with double-
stranded NF-B consensus oligonucleotides labeled at
the 3 terminal by biotin. The samples were separated
on 6% PAGE and then transferred to a nitrocellulose
membrane by electroblotting. After incubation with
1 g/ml streptoavidin conjugated to horseradish perox-
idase, peroxidase activity on the membrane was
detected using an enhanced chemiluminescence
substrate system.
Measurement of [Ca2+]i
To determine the eVects of magnolol on the oxLDL-
induced intracellular calcium rise, HUVECs were
seeded onto 24-mm glass coverslips, pretreated with
magnolol (2.5–20 M) for 2 h and then stimulated with
oxLDL (200 g/ml) for 16 h. The cells on coverslips123
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in M199 for 30 min at 37°C. After loading, the cells
were washed with HEPES buVer (mM) (NaCl, 131;
KCl, 5; CaCl2, 1.3; Mg2SO4, 1.3; KH2PO4, 0.4; HEPES,
20; glucose 25, pH 7.4) to remove excess Xuorescence
dye. Then, the Xuorescence of the cells from each cov-
erslip was measured and recorded using an inverted
Olympus microscope IX-70. [Ca2+]i in endothelial cells
were monitored by alternating excitation wavelengths
between 340 and 380 nm and an emission wavelength
of 510 nm with a Delta Scan System (Photon Technol-
ogy International, Princeton, NJ, USA), and calculated
using Grynkiewicz’s method (Grynkiewicz et al. 1985).
Measurement of mitochondria membrane potential
To explore the eVects of magnolol on the mitochondria
membrane potential (m), the lipophilic cationic
probe Xuorochrome 5,58,6,68-tetraethylbenzimidazol-
carbocyanine iodide (JC-1) was used. JC-1 exists either
as a green Xuorescent monomer at a depolarized mem-
brane potential or as a red Xuorescent J-aggregate at a
hyperpolarized membrane potential. JC-1 exhibits
potential-dependent accumulation in mitochondria, as
indicated by the Xuorescence emission shift from 530 to
590 nm. After a treatment of oxLDL (200 g/ml) for
16 h in the presence or absence of 5 M magnolol, cells
(5 £ 104 cells/24-well plates) were rinsed with M199, and
JC-1 (5 M) was loaded. After 20 min incubation at
37°C, cells were examined under a Xuorescent micro-
scope. Determination of the m was also carried out
using a FACScan Xow cytometer (Bedner et al. 1999).
Isolation of cytosolic fractions for cytochrome 
c analysis
After a treatment of oxLDL in the presence and
absence of magnolol (2.5–20 M), the cells were col-
lected and lysed with lysis buVer (20 mmol/l HEPES/pH
7.5, 250 mmol/l sucrose, 10 mmol/l KCl, 2 mmol/l MgCl2,
1 mmol/l EDTA, 1 mmol/l DTT, protease inhibitor
cocktail) for 20 min on ice. The samples were homoge-
nized via 10 passages through a 2-gauge needle. The
homogenate was centrifuged at 12,000 rpm for 20 min at
4°C. Protein was measured by the method used by Brad-
ford (1976). A volume of cell lysates containing 30 g of
protein was analyzed by Western blot analysis for cyto-
chrome c (1:1,000) and -actin (1:50,000).
Measurement of active caspase-3
To explore the eVects of magnolol on the oxLDL-
induced caspase-3 activation, HUVECs were pretreated
with 5 M magnolol for 2 h and then stimulated with
oxLDL (200 g/ml) for 16 h; and the contents of active
caspase-3 were detected by Xow cytometry, using a
commercial Xuorescein active caspase kit (Mountain
View, CA, USA) (Telford et al. 2002).
Statistical analyses
Results are expressed as mean § SEM, and data were
analyzed for signiWcant diVerence using Student’s t-
test. Statistical signiWcance was deWned as P < 0.05.
Results
EVects of magnolol on the copper-induced oxidative 
modiWcation of LDL
The copper-induced oxidation of LDL in the presence
of various concentrations of magnolol was determined
by the kinetics of conjugated diene formation, MDA
formation and electrophoretic mobility. When LDL
was oxidized by cupric ions, a very short lag-time (near
70 min) was observed. On the other hand, in the pres-
ence of various concentrations of magnolol (2.5–
20 M), no lag times were detected by 300 min, indicat-
ing that oxidation of LDL was delayed (Fig. 1a). The
eVective concentrations of magnolol inhibiting the cop-
per ion-induced LDL oxidation were subsequently
studied by measurement of TBARS. As shown in
Fig. 1b, the presence of magnolol protected LDL from
copper-induced oxidation, as indicated by the forma-
tion of nmol MDA per mg protein (¡0.64 § 0.2;
18.9 § 2.0; 16.1 § 2.9; 14.0 § 2.2; 10.8 § 1.8; 10.0 § 1.0
for native LDL, copper-treated LDL and LDL with
combined treatment of copper and magnolol at 2.5, 5,
10, and 20 M, respectively; all P < 0.01). The relative
mobility of oxidized LDL was approximately 1.7-fold
faster than that of native LDL (Fig. 1c, lane 1 vs. lane 2
from left). A signiWcant decrease in the mobility was
observed in all four treatments with various concentra-
tions of magnolol (2.5–20 M). These results further
indicate that magnolol is a potent antioxidant.
Magnolol inhibited the oxLDL-induced cytotoxicity 
on HUVECs in a concentration-dependent manner
Phase-contrast microscopy was performed to examine
the protective eVects of magnolol on morphological
features on the cultured HUVECs exposed to oxLDL.
After a 16-h exposure to a cytotoxic concentration of
oxLDL (200 g of protein/ml of LDL), the number of
shrinking cells or cells with blebbing membranes were123
Arch Toxicol (2007) 81:421–432 425signiWcantly reduced by the presence of magnolol
(Fig. 2a). The viability of cells incubated with oxLDL
in the absence or presence of indicated concentrations
of magnolol was carried out by MTT assay (32 § 5%
vs. 32 § 4% (P = NS), 33 § 5% (P < 0.01), 54 § 7%
(P < 0.01), 82 § 8% (P < 0.01), 104 § 10% (P < 0.01),
115 § 8% (P < 0.01), 115 § 5% (P < 0.01) for oxLDL,
oxLDL with 0.1, 0.5, 1, 2.5, 5, 10, 20 M magnolol com-
pared to control, respectively, Fig. 2b), and the mem-
brane permeability was assayed by LDH release
[245 § 7% vs. 247 § 6% (P = NS), 239 § 5.0%
(P = NS), 246 § 10% (P = NS), 179 § 11% (P < 0.01),
139 § 25% (P < 0.01), 111 § 16% (P < 0.01), 72 § 2%
(P < 0.01) for oxLDL, oxLDL with 0.1, 0.5, 1, 2.5, 5, 10,
20 M magnolol compared to control, respectively,
Fig. 2C]. The 50% eVective concentration (ED50) was
calculated to be 1.7 M for cell viability and 3.1 M for
cytotoxicity. Therefore, 2.5–20 M were Wnally
selected for the following experiments. To further
ascertain the induction of apoptosis in HUVECs,
oxLDL-treated cells were biochemically analyzed via
TUNEL and DAPI staining assay. As shown in Fig. 3,
cells incubated with oxLDL for 16 h showed typical
apoptosis, including the formation of condensed and
fragmented nuclei, which was not observed in the 5 M
magnolol pretreated-HUVECs. The results of cell via-
bility assay together with phenotypic observation of
apoptosis under microscopy and Xow cytometry sug-
gest that magnolol is a potent inhibitor of the oxidized
LDL-induced cytotoxicity in cultured HUVECs.
Magnolol decreased the suppression of superoxide 
dismutase which led to a reduction in oxLDL-induced 
ROS generation
We next turned our attention to ROS as a potential
factor related to the oxLDL-induced endothelial cell
injury and assayed the activity of the endogenous anti-
oxidant. Pretreatment with magnolol (2.5–20 M) of
HUVECs for 2 h before exposure to 200 g/ml of
oxLDL signiWcantly decreased ROS generation in a
dose-dependent and time-dependent manner (all
P < 0.01) as shown in Fig. 4a. In accordance with these
Wndings, magnolol also reduced the suppression of
SOD activity as shown in Fig. 4b (0.60 § 0.03,
0.31 § 0.03, 0.44 § 0.03, 0.44 § 0.03, 0.49 § 0.03 and
0.58 § 0.04% U/mg protein for control, oxidized LDL
and oxidized LDL with 2.5, 5, 10, 20 M magnolol pre-
treatment, respectively; all P < 0.01).
Magnolol inhibited the oxLDL-induced NF-B 
activation of HUVECs
NF-B, a potent transcription factor, is thought to be
important in oxidative stress and implicated in athero-
sclerosis since activated NF-B is present in human
atherosclerotic lesions (Brand et al. 1996). We
therefore examined the eVects of magnolol on NF-B
Fig. 1 EVects of magnolol on copper-induced oxidation of LDL
measured as an increase in lag time of diene formation (a), decrease
in TBARS (b) and electrophoretic mobility (c) in the absence or
presence of the indicated concentrations of magnolol. Data are
shown as the mean § SEM of three independent analyses. #P < 0.01
versus native LDL; *P < 0.01 versus oxLDL treatment
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shift assay detected an increase band upwards and an
unbound band in a mixture of biotin-labeled NF-B
consensus oligonucleotides with the nuclear fraction of
HUVECs treated with oxLDL, and magnolol
prevented NF-B activation at all concentrations.
Magnolol reduced oxLDL-induced intracellular 
calcium accumulation
Unlike oxLDL-induced ROS generation and NF-B
activation that happened within 2 h, cytotoxicity
caused by oxLDL needs a longer incubation period.
Thus, HUVECs were treated with oxLDL for 16 h in
the following experiments. To investigate the eVects
of exposure of endothelial cells to oxLDL on intracel-
lular calcium, we incubated HUVECs with a cyto-
toxic concentration (200 g/ml) of oxLDL in either
the absence or presence of magnolol. As shown in
Fig. 6, the basal [Ca2+]i increased in oxLDL-treated
cells after 16 h, whereas magnolol signiWcantly inhib-
ited the oxLDL-enhanced intracellular calcium rise
(49 § 1, 301 § 20, 104 § 3, 85 § 3, 90 § 2, 86 § 3 nM
for control, oxidized LDL and oxidized LDL
combined with 2.5, 5, 10, 20 M magnolol, respec-
tively; all P < 0.01).
Fig. 2 EVects of magnolol on 
oxDL-induced endothelial 
cell death. HUVECs were 
incubated with oxLDL 
(200 g protein/ml) in the ab-
sence (middle) and presence 
(right) of 5 M of magnolol 
for 16 h. Photomicrographs 
from phase-contrast micros-
copy (a). Viability was deter-
mined via MTT assay (b) and 
LDH release (c). The values 
represent means § SEM from 
three separate experiments. 
#P < 0.01 versus control; 
*P < 0.01 versus oxLDL 
treatment
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permeability transition
To examine whether inhibition of mitochondrial dis-
ruption may account for the anti-apoptotic eVects of
magnolol, we tested the eVects of oxLDL on mitochon-
drial permeability. When HUVECs were exposed to
oxLDL (200 g/ml), the m was depolarized, as
shown by the increase in green Xuorescence (Fig. 7a,
middle panel). Pretreatment with magnolol reduced
the change in m as indicated by repression of green
Xuorescence and restoration of red Xuorescence
(Fig. 7a, right panel). These Wndings were supported
using Xow cytometry (Fig. 7b). OxLDL caused a
marked increase in JC1 green Xuorescence (middle)
compared to control (left). Pretreatment with magno-
lol caused a marked inhibition of oxLDL-induced
apoptosis (right). Indeed, disruption of mitochondrial
membrane function resulted in the speciWc release of
the mitochondrial enzyme cytochrome c into the cyto-
sol. Cytosolic proteins were separated and detected by
Western blot. As shown in Fig. 7c, incubation of
HUVECs with oxLDL for 16 h induced the release of
cytochrome c into the cytosolic fraction »3 folds com-
pared with the cytochrome c amount determined in the
cytosolic fraction of control cells. Notably, magnolol
signiWcantly prevented oxLDL-induced cytochrome c
release.
Magnolol reduced oxLDL-induced caspase-3 
activation
It is well known that oxLDL-induced cytochrome c
release may lead to activation of caspase-3, an eVector
of apoptosis. We subsequently determined the active
form of caspase-3 using Xow cytometry. As shown in
Fig. 8, active caspase-3 was signiWcantly increased in
cells treated with oxLDL for 16 h. In contrast, the acti-
vation of caspase-3 by oxLDL was suppressed by
approximately 50% in cells pretreated with 5 M of
magnolol.
Discussion
OxLDL exhibit a wide range of biological eVects on
cultured arterial cells including apoptosis. Evidence
has been presented that oxidized lipids from oxLDL
induce modiWcation of cell protein structure, elicit
ROS generation and lipid peroxidation of cellular
Fig. 3 EVects of magnolol on 
oxidized LDL-induced 
endothelial cell apoptosis. 
HUVECs were incubated 
with oxLDL (200 g protein/
ml) in the absence (middle) 
and presence (right) of 5 M 
magnolol for 16 h. Top Cells 
stained with DAPI. Middle 
Cells stained using TUNEL 
assay. Bottom Flow cytomet-
ric analysis. (control white, 
oxLDL black, oxLDL with 
magnolol gray)123
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pathways and gene expression (Napoli 2003). In the
present study, we demonstrated that magnolol, an
active component isolated from the herb ‘Houpo’
(Magnolia oYcinalis), exerted potent inhibitory eVects
on oxLDL-induced apoptosis through inhibition of
ROS generation. Our Wndings indicate that the anti-
oxidative actions of magnolol inhibited the copper-
induced LDL oxidation (Fig. 1). Magnolol reduced
apoptosis and cell death are especially relevant since
increased endothelial cell apoptosis may initiate ath-
erosclerotic lesions, which are prone to rupture at vul-
nerable plaque (Littlewood and Bennett 2003). Results
from our experiments indicated that cell death of
HUVECs exposed to a toxic concentration of oxLDL
(200 g protein/ml) could be reversed by magnolol;
evidenced by DAPI stain and by TUNEL assay
(Fig. 2). OxLDL induced time-dependent increase in
ROS production during 2 h as well as decreased SOD
activities were reversed in the presence of magnolol. In
addition, several apoptotic signaling pathways includ-
ing intracellular calcium accumulation and subsequent
mitochondrial membrane potential collapse, cyto-
chome c release and activation of caspase 3 caused by
oxLDL were also inhibited by magnolol. All these Wnd-
ings strongly indicate the anti-oxidative eVects of mag-
nolol in response to oxLDL treatment in HUVECs.
High levels of oxLDL in endothelial membrane can
foster the formation of a necrotic lipid core by apopto-
sis in atherosclerotic lesions (Heermeier et al. 1999).
There is a plethora of signal transduction and nuclear
events that are involved in the phenomenon, including
TNFR1 and TNFR2 activation, the complex cascade of
kinases, regulatory events of the Bcl-2 family of genes,
activation of death-eVector caspases and sphingomye-
linase, and regulatory action of the transcription fac-
tors (Escargueil-Blanc et al. 1998; Harada-Shiba et al.
1998; Sata and Walsh 1998). NF-B is often viewed as a
global regulator of cytokines and mitogenic products
that may inXuence vascular smooth muscle prolifera-
tion as well as endothelial apoptosis and contribute to
atherogenesis (Selzman et al. 1999). Several lines of
evidence suggest a role for ROS as a common and crit-
ical intermediate for various NF-B activating signals.
This conclusion is based largely on the inhibition of
NF-B activation by a variety of antioxidants (Schreck
et al. 1992) and by overexpression of antioxidant
enzymes. It was also noted that NF-B expression was
considerably increased in endothelial cells following
Fig. 4 Time course of inhibitory eVects of magnolol on oxLDL-
induced ROS production in HUVECs. After preincubation for
2 h with the indicated concentrations of magnolol (2.5–20 M),
HUVECs were incubated with DCF-AM for 1 h followed by
incubation with 200 g/ml oxLDL. a Fluorescence distribution of
DCF-AM oxidation was expressed as a percentage of increased
intensity. b The activities of SOD in HUVECs stimulated with
oxLDL for 2 h in the absence or presence of magnolol were deter-
mined. Data show the mean § SEM of three independent analy-
ses. #P < 0.01 versus control; *P < 0.01 versus oxLDL treatment
R
O
S 
(%
 
o
f i
nc
re
as
e)
0
50
100
150
200
250
300
350
control
oxLDL
oxLDL+magnolol 2.5 µM
oxLDL+magnolo l5 µM
oxLDL+magnolol 10 µM
oxLDL+magnolol 20µM
0 5 15 30 60 120
(min)
SO
D
 a
ct
iv
ity
 (u
nit
/m
g p
rot
ein
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
oxLDL (200 µg/ml) - + + + + + 
magnolol (µM) - - 2.5 5 10 20 
#
* *
*
*
(A)
(B)
Fig. 5 EVects of magnolol on NF-B activation stimulated by ox-
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bation for 1 h. Nuclear extracts from these cells were analyzed by
EMSA with a labeled probe. A representative autoradiograph
from three experiments is shown
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Arch Toxicol (2007) 81:421–432 429oxLDL treatment (Cominacini et al. 2000) and the
presence of oxLDL is associated with activation of the
NF-B in the endothelium of an animal model (Calara
et al. 1998). Activation of NF-B coordinates the
expression of vascular cell adhesion molecules
(VCAM-1) (Neish et al. 1992), E-selectin (Collins et al.
1993) and monocyte chemoattractant protein-1 (MCP-
1) gene (Lindner 1998) may lead to an adherence of
endothelial cells and leukocytes which is associated
with initial events in the development of atheroscle-
rotic lesion. Therefore, suppression of NF-B can be
expected to result in prevention of atherogenesis. This
was supported by our Wnding that the activation of
NF-B by oxLDL was signiWcantly inhibited by pre-
treatment of magnolol (Fig. 5). Whether magnolol
reduced oxLDL-induced NF-B activation is involved
in the release of inXammatory cytokines requires
further study.
There is an increasing interest in the application of
antioxidants for the prevention and treatment of car-
diovascular disease since oxygen-derived free radicals
and alteration of intracellular Ca2+ ion homeostasis
are now considered major contributing factors to ath-
erosclerotic coronary artery disease. An intense,
delayed, and sustained calcium signal is a trigger of
cell death but the initial targets and the subsequent
sequence of events leading to cell death are only
partly understood (Vindis et al. 2005). Previous stud-
ies demonstrated that calcium channel blockers inhi-
bite experimental atherosclerosis in cholesterol-fed
animals (Cristofori et al. 2000), improve endothelial
cell functions by upregulating the nitric oxide system
(Ding and Vaziri 2000), and downregulating the
endothelial receptor for oxidized LDL (LOX-1) as
well as inhibiting the CPP32-like protease activity
(Sugano et al. 2002). In addition, magnolol block
receptor-operated cation channel, voltage dependent
calcium channel and inhibit calcium release from the
sarcolemmal membrane through blocking InsP3-sen-
sitive and ryanodine-sensitive pathways on distal
colon of guinea pig in vitro (Bian et al. 2006), inhibit
calcium inXux through voltage-operated calcium
Fig. 6 EVects of magnolol on 
cytoplasmic Ca2+ increase 
stimulated by oxLDL in fura 
2-loaded HUVECs. Images 
were processed as indicated in 
Materials and methods. Cal-
cium changes are color coded 
(color bar) such that warm 
colors indicate high calcium. 
Upper left control; upper mid-
dle oxLDL; upper right ox-
LDL plus magnolol 2.5 M; 
lower left oxLDL plus magno-
lol 5 M; lower middle oxLDL 
plus magnolol 10 M; lower 
right oxLDL plus magnolol 
20 M. The values represent 
means § SEM of more than 
250 individual cells from three 
separate experiments. 
*P < 0.01 versus oxLDL 
treatment
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430 Arch Toxicol (2007) 81:421–432channels in porcine trachea (Zhai et al. 2003). This
may explain, at least partially, the mechanisms under-
lying the protective eVects of magnolol against
oxLDL-induced intracellular calcium accumulation.
The oxidant stress imposed by oxLDL appears to
activate the signaling pathways leading to apoptosis of
endothelial cells, since ROS generation is the earliest
apoptotic signal and it usually happens within 5 min of
oxLDL addition. ROS generation may inhibit Ca2+-
ATPases, and lead to a sustained elevation of [Ca2+]i,
which is associated with mitochondrial dysfunction
mediated by loss of membrane potential and release of
cytochrome c. Accordingly, the anti-apoptotic eVects
of magnolol are hypothesized to be resulted from its
inhibitory eVect on ROS generation that, in turn,
represses the release of endothelial [Ca2+]i and stabi-
lizes the mitochondrial membrane, thereby preventing
the release of mitochondrial protein cytochrome c, a
molecule required for the activation of caspase-3 that
executes the cell death program (Littlewood and Ben-
Fig. 7 EVects of magnolol on 
mitochondrial transmem-
brane permeability transition. 
a m was assessed via a sig-
nal from monomeric and J-
aggregate JC-1 Xuorescence, 
as described in Materials and 
methods. Left No treatment; 
middle oxLDL; and right ox-
LDL+ 5 M magnolol. b JC-1 
Xuorescence was conWrmed by 
using Xow cytometry. c cyto-
chrome c was detected by 
Western blotting as described 
in Materials and methods. 
Lane 1 control; lane 2 oxLDL; 
lane 3, 4, 5, 6, oxLDL + 2.5, 5, 
10, 20 M magnolol, 
respectively
Fig. 8 EVects of magnolol on 
oxLDL-induced caspase-3 
activation. HUVECs were 
incubated with oxLDL in the 
absence (right) and presence 
(middle) of 5 M magnolol for 
16 h. Activation of caspase-3 
was examined using Xow 
cytometry. (control white, 
oxLDL black, oxLDL with 
magnolol gray)123
Arch Toxicol (2007) 81:421–432 431nett 2003). Pathways to caspase-3 activation have been
identiWed that are either dependent on or independent
of mitochondrial cytochrome c release and caspase-9
function. In some instance, apoptotic cell death does
not always involve the cytochrome c-dependent activa-
tion of caspase-3 (Indrajit et al. 2006). Our data dem-
onstrated that pretreatment HUVECs with 5 M
magnolol almost complete abolished the oxLDL-
induced transmembrane permeability transition of
mitochondria (Fig. 7) but only suppressed the activa-
tion of caspase-3 by approximately 50% (Fig. 8). We
assumed that magnolol at dose of 5 M was sensitive
enough to reverse the cytochrome c-dependent but not
cytochrome c-independent activation of caspase 3.
In accordance with our observations, several previ-
ous studies have demonstrated that magnolol has the
beneWcial functions of anti-oxidant and anti-inXamma-
tory activities, which stem from the inhibition of neu-
trophil inWltration and reactive oxygen species
production (Liou et al. 2003a, b; Park et al. 2004) and
protection of mitochondrial respiratory chain enzyme
activity against NADPH-induced peroxidative stress
(Haraguchi et al. 1997). With regard to the underlying
mechanisms of anti-inXammation, magnolol suppresses
IL-6-induced signal transducer and activator of tran-
scription protein 3 (STAT3) activation and gene
expression in endothelial cells (Chen et al. 2006) and
magnolol acts as a potent inhibitor of NF-B
activation, which is a key transcription factor in the
expression of inXammatory cytokines (Lee et al. 2005).
In addition to these reported beneWcial eVects, earlier
studies have shown that magnolol relaxes smooth mus-
cle due to the blockade of receptor-operated cation
channels and voltage-operated Ca2+ channels (Ko et al.
2003; Lu et al. 2003). Taken together, all these Wndings
suggest that magnolol might be a plausible lead candi-
date for further development in the prevention of
cardiovascular diseases.
In summary, results from our experiments indicate
that magnolol, a natural aromatic product from
plants, could prevent atherogenesis, probably via its
anti-oxidative eVects. In addition, magnolol inhibited
oxLDL-induced apoptosis in HUVECs. Our Wndings
on the intracellular signaling pathways modulating
the oxidative insults induced by oxLDL in endothelial
cultures shed some light on the potential implications
of magnolol in the prevention of the atherosclerotic
process.
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